Abstract Details

Title Assessing the Utility and Attitudes Towards Molecular Testing in Neuro-Oncology: A Survey of the Society of Neuro-Oncology Members

Topic Neuro-oncology

Presentation(s) Neuro-oncology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 010

Objective Molecular testing (MT) is utilized in Neuro-Oncology with increasing frequency. The aim of this study was to determine the practice patterns of clinicians to acquire this information, interpret MT and utilize results for patient care, and identify unmet needs in the practical clinical application of MT.

Background The molecular landscape of central nervous system (CNS) tumors has continued to become more defined and comprehensive over the last few decades. This increasing understanding of tumor biology has allowed for more accurate diagnostic testing, and has driven advancements in precision medicine toward the development of novel targeted therapies.

Design/Methods We conducted a voluntary on-line survey of providers within the Society for Neuro-Oncology (SNO) membership database between March and April 2019.

Results We received 152 responses out of 2,022 SNO members (7.5% of membership). 88.8% percent of respondents routinely order MT. Of those who do not order MT on all patients, testing is preferentially performed in younger patients or those with midline tumors. 82.8% use MT in recurrent gliomas. Other common indications included: metastatic tumors, meningioma, and medulloblastoma. Many providers utilize more than one testing resource (36.0%), most frequently using in-house (41.8%) over commercially available panels. 78.1% used the results for clinical decision-making, with BRAF, EGFR/ALK, and H3K27 mutations most commonly directing treatment decisions. Approximately half (48.5%) of respondents have molecular tumor boards at their institutions. Respondents would like to see SNO-endorsed official guidelines on MT, organized lists of targeted agents available for specific mutations, a database of targetable mutations and clinical trials, and more educational programs on MT.

Conclusions MT in neuro-oncology is routinely performed and incorporated into clinical decision making. There is a need for more concise guideline updates, society recommendations, and practical methods for incorporating the expanding genomic data resulting from MT of CNS tumors into daily clinical practice.

Authors/Disclosures
Shannon Fortin Ensign, MD, PhD (Mayo Clinic) PRESENTER	Dr. Fortin Ensign has nothing to disclose.
Maya Hrachova, DO (Home)	Dr. Hrachova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SpringWorks Therapeutics.
	No disclosure on file
Maciej M. Mrugala, MD, PhD, MPH, FAAN (Mayo Clinic)	Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Veevo Biomedicines Inc. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arbor Pharmaceuticals. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra-Zeneca. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyiatec . The institution of Dr. Mrugala has received research support from Arbor Pharmaceuticals. Dr. Mrugala has a non-compensated relationship as a Program Director with Society for Neuro-Oncology that is relevant to AAN interests or activities.

��ɫ��

��ɫ��